NaDeNo
About
NaDeNo is a Norwegian biotech with a nanoparticle-based drug delivery technology for hard-to-deliver drugs and a lead asset for ovarian cancer. NaDeNo builds on over a decade of research as a spin-off from SINTEF, one of Europe’s leading research organizations.
The platform uses polymeric nanoparticles to encapsulate hydrophobic drugs in a patented one-step process, without chemically modifying the active ingredient. This supports scalable and sustainable manufacturing while enabling targeted delivery through surface customization. Our lead candidate, PACAB-002, is intended to eradicate peritoneal micrometastases in ovarian cancer, has recieved EMA Orpahn Drug Designation for ovarian cancer and will enter Phase 1 clinical trial in early 2027.
NaDeNo is an EIC Accelerator beneficiary, awarded €10 million in blended finance. We are part of AstraZeneca’s BioVentureHub, selected based on scientific merit and potential for synergies. Platform projects are ongoing, including feasibility of oral delivery with a big pharma partner.
Through pharma partnerships, NaDeNo aims to expand the clinical impact of hard-to-deliver drugs.
Business Domain / 分野
Disease Area / 疾患領域
Modalities / モダリティ
Technologies / 技術
Business Type / 業種
Additional Information
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術